AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11426345 — intervention group
Group type: COMPARATOR
Intervention: Testosterone cream (0.8%)
Number of subjects: 42
Study 10965083 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrolingual-Spray
Number of subjects: 28
Study 10965083 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (NTG) tablets
Number of subjects: 28
Study 8981709 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined temporal corneal phacoemulsification and superior trabeculectomy with low-dose 5-FU
Number of subjects: 40
Study 8981709 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy alone with low-dose 5-FU
Number of subjects: 40
Study 1290475 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g of oral enterically coated 4‐aminosalicylic acid
Number of subjects: 40
Study 1290475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 6365490 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 28
Study 6365490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 30360762 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education (PNE) training
Number of subjects: 0
Study 30360762 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 26531051 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical natamycin
Number of subjects: 323
Study 26531051 — intervention group
Group type: COMPARATOR
Intervention: Topical voriconazole
Number of subjects: 323
Study 26531051 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical natamycin or voriconazole (corrected for treatment arm)
Number of subjects: 323
Study 24523562 — intervention group
Group type: EXPERIMENTAL
Intervention: D1-like receptor activation with l-DOPA (25 mg)
Number of subjects: 0
Study 24523562 — intervention group
Group type: EXPERIMENTAL
Intervention: D1-like receptor activation with l-DOPA (100 mg)
Number of subjects: 0
Study 24523562 — intervention group
Group type: EXPERIMENTAL
Intervention: D1-like receptor activation with l-DOPA (200 mg)
Number of subjects: 0
Study 24523562 — intervention group
Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 0
Study 22783919 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine (Asacol®) 1.6 gm b.i.d. for 12 weeks
Number of subjects: 20
Study 22783919 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 20
Study 20727209 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic Walking
Number of subjects: 60
Study 20727209 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise intervention)
Number of subjects: 60
Study 17438710 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine therapy
Number of subjects: 222
Study 17438710 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy and radiotherapy
Number of subjects: 222
Study 17438710 — intervention group
Group type: EXPERIMENTAL
Intervention: Socio-economic factors (educational level, matrimonial status, presence of under-age children)
Number of subjects: 222
Study 16239090 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release clarithromycin (CLA-ER) 1000 mg once a day for 5 days
Number of subjects: 362
Study 16239090 — intervention group
Group type: COMPARATOR
Intervention: Telithromycin (TELI) 800 mg once a day for 5 days
Number of subjects: 362
Study 11877352 — intervention group
Group type: EXPERIMENTAL
Intervention: Glanzmann thrombasthenia patients
Number of subjects: 7
Study 11877352 — intervention group
Group type: COMPARATOR
Intervention: Measurement of intima-media thickness
Number of subjects: 7
Study 11877352 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients lacking both alpha(IIb)beta(3) and alpha(v)beta(3) complexes
Number of subjects: 7
Study 11877352 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients lacking only alpha(IIb)beta(3)
Number of subjects: 7
Study 10223677 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect therapy (group 2)
Number of subjects: 45
Study 10223677 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct with indirect therapy (group 3)
Number of subjects: 45
Study 10223677 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group 1)
Number of subjects: 45
Study 7602445 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Community (TC)
Number of subjects: 723
Study 7602445 — intervention group
Group type: COMPARATOR
Intervention: Community Residence (CR)
Number of subjects: 723
Study 2366172 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 0
Study 2366172 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen with codeine
Number of subjects: 0
Study 30590610 — intervention group
Group type: EXPERIMENTAL
Intervention: Male flocks
Number of subjects: 14
Study 30590610 — intervention group
Group type: COMPARATOR
Intervention: Female flocks
Number of subjects: 14
Study 30390620 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus Tai Chi intervention for 20 weeks
Number of subjects: 150
Study 30390620 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 150
Study 27929319 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychomotor intervention program (PIP); activities targeting body awareness, body concepts, space concepts, and time concepts; conducted three times a week for 10 weeks.
Number of subjects: 28
Study 27929319 — intervention group
Group type: COMPARATOR
Intervention: Regular rehabilitation center educational program (control group); no PIP intervention; same duration as experimental group.
Number of subjects: 28
Study 24439830 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine+Sertraline
Number of subjects: 259
Study 24439830 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine+Placebo
Number of subjects: 259
Study 22366535 — intervention group
Group type: EXPERIMENTAL
Intervention: STN‐DBS alone
Number of subjects: 16
Study 22366535 — intervention group
Group type: EXPERIMENTAL
Intervention: l‐dopa alone
Number of subjects: 16
Study 22366535 — intervention group
Group type: EXPERIMENTAL
Intervention: STN‐DBS plus l‐dopa
Number of subjects: 16
Study 22366535 — intervention group
Group type: COMPARATOR
Intervention: Without STN‐DBS and without l‐dopa
Number of subjects: 16
Study 22366535 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 16
Study 22366535 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflex blinking (STN‐DBS and l‐dopa)
Number of subjects: 16
Study 20151785 — intervention group
Group type: EXPERIMENTAL
Intervention: BTX‐A‐1 (30 units)
Number of subjects: 0
Study 20151785 — intervention group
Group type: EXPERIMENTAL
Intervention: BTX‐A‐2 (256 units total)
Number of subjects: 0
Study 20151785 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized photographic numerical assay
Number of subjects: 0
Study 20151785 — intervention group
Group type: EXPERIMENTAL
Intervention: BTX‐A‐2 (3:1 ratio to BTX‐A‐1)
Number of subjects: 0
Study 20151785 — intervention group
Group type: COMPARATOR
Intervention: BTX‐A‐1 and BTX‐A‐2
Number of subjects: 0
Study 19022007 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic low-energy shock wave therapy (SWT) applied to the site of vein harvesting after wound closure (n = 50)
Number of subjects: 100
Study 19022007 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 50)
Number of subjects: 100
Study 15800098 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer + clinic intervention (peer education supplemented by individual risk reduction counselling by a clinician)
Number of subjects: 1000
Study 15800098 — intervention group
Group type: COMPARATOR
Intervention: Peer only intervention (condom promotion by peer educators only)
Number of subjects: 1000
Study 15800098 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer + clinic intervention
Number of subjects: 1000
Study 12185103 — intervention group
Group type: EXPERIMENTAL
Intervention: CPA‐5‐100 (5 mg/day CPA + 100 mg/week TE)
Number of subjects: 18
Study 12185103 — intervention group
Group type: EXPERIMENTAL
Intervention: CPA‐5‐200 (5 mg/day CPA + 200 mg/week TE)
Number of subjects: 18
Study 12185103 — intervention group
Group type: COMPARATOR
Intervention: CPA‐5‐100
Number of subjects: 18
Study 12185103 — intervention group
Group type: COMPARATOR
Intervention: CPA‐5‐200
Number of subjects: 18
Study 10230181 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant medications
Number of subjects: 0
Study 8694673 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir 500 mg
Number of subjects: 987
Study 8694673 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir 1000 mg
Number of subjects: 987
Study 8694673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 987
Study 8694673 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir
Number of subjects: 987
Study 1992688 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodide salt administered to group A (n = 17)
Number of subjects: 35
Study 1992688 — intervention group
Group type: COMPARATOR
Intervention: Control group B (n = 18)
Number of subjects: 35
Study 6352208 — intervention group
Group type: EXPERIMENTAL
Intervention: Inorganic Cr trichloride
Number of subjects: 43
Study 6352208 — intervention group
Group type: EXPERIMENTAL
Intervention: Brewer's yeast containing GTF
Number of subjects: 43
Study 6352208 — intervention group
Group type: EXPERIMENTAL
Intervention: Brewer's yeast extract without GTF
Number of subjects: 43
Study 6352208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 31763315 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 30
Study 31763315 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole
Number of subjects: 30
Study 31763315 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 30
Study 27513191 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 23
Study 27513191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 25633319 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleasant odor (rose)
Number of subjects: 62
Study 25633319 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpleasant odor (leather)
Number of subjects: 62
Study 25633319 — intervention group
Group type: COMPARATOR
Intervention: No odor exposure
Number of subjects: 62
Study 25078977 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled-release (CR) 82.5, 165, 330 or 660 mg/day administered once daily (QD)
Number of subjects: 84
Study 25078977 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled-release (CR) two-tablet dose
Number of subjects: 84
Study 25078977 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin immediate-release (IR) 75, 150, 300 or 600 mg/day administered either twice (BID) or three times (TID) a day
Number of subjects: 84
Study 25078977 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled-release (CR)
Number of subjects: 84
Study 21297404 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia Enhanced Web site
Number of subjects: 34
Study 21297404 — intervention group
Group type: COMPARATOR
Intervention: Basic Web site
Number of subjects: 34
Study 19321400 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder pressure measurement (BP) using 50 mL of sterile saline instilled into the bladder, measured in the supine position.
Number of subjects: 75
Study 19321400 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acute abdominal complaints).
Number of subjects: 75
Study 17257473 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone extended release (5- to 10-mg increments every 12 h, every 3-7 days)
Number of subjects: 325
Study 17257473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study 15302288 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 56
Study 15302288 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 150 mg/day
Number of subjects: 56
Study 15302288 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE) 0.625 mg/day
Number of subjects: 56
Study 15302288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 11599506 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB in standard encapsulation (SH)
Number of subjects: 0
Study 11599506 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB in time release capsule (TRH)
Number of subjects: 0
Study 11599506 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 0
Study 9543145 — intervention group
Group type: EXPERIMENTAL
Intervention: sICAM-1 serum levels in GD patients developing active inflammatory ophthalmopathy (group 1)
Number of subjects: 103
Study 9543145 — intervention group
Group type: EXPERIMENTAL
Intervention: sICAM-1 serum levels in GD patients developing ophthalmopathy without clinical retroorbital inflammation (group 1)
Number of subjects: 103
Study 9543145 — intervention group
Group type: EXPERIMENTAL
Intervention: sICAM-1 serum levels in GD patients not developing ophthalmopathy (group 2)
Number of subjects: 103
Study 9543145 — intervention group
Group type: COMPARATOR
Intervention: sICAM-1 serum levels in both groups compared to healthy controls
Number of subjects: 103
Study 8303754 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirilazad mesylate at 0.6 mg/kg per day
Number of subjects: 111
Study 8303754 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirilazad mesylate at 2.0 mg/kg per day
Number of subjects: 111
Study 8303754 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirilazad mesylate at 6.0 mg/kg per day
Number of subjects: 111
Study 8303754 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 111
Study 8303754 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of Tirilazad
Number of subjects: 111
Study 2592475 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard instructions 'not true' for the CBCL 0 category
Number of subjects: 0
Study 2592475 — intervention group
Group type: COMPARATOR
Intervention: Modified instructions 'never or not true' for the CBCL 0 category
Number of subjects: 0
Study 29772855 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation
Number of subjects: 48
Study 29772855 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 48
Study 26595359 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dairy (LFD)
Number of subjects: 37
Study 26595359 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-based control (CNT)
Number of subjects: 37
Study 25652120 — intervention group
Group type: EXPERIMENTAL
Intervention: Kato-Katz technique
Number of subjects: 1445
Study 25652120 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality control of Kato-Katz technique
Number of subjects: 1445
Study 23652908 — intervention group
Group type: EXPERIMENTAL
Intervention: tretinoin plus topical corticosteroids
Number of subjects: 50
Study 23652908 — intervention group
Group type: COMPARATOR
Intervention: vehicle plus topical corticosteroid
Number of subjects: 50
Study 21910803 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF-α treatment
Number of subjects: 40
Study 17561259 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.5%
Number of subjects: 122
Study 17561259 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 122
Study 17561259 — intervention group
Group type: COMPARATOR
Intervention: Normal group (no treatment)
Number of subjects: 122
Study 16055455 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID (diclofenac)
Number of subjects: 74
Study 16055455 — intervention group
Group type: COMPARATOR
Intervention: Non-NSAID (paracetamol and codeine)
Number of subjects: 74
Study 12532174 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg s.c./24 h
Number of subjects: 7344
Study 12532174 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 7344
Study 12532174 — intervention group
Group type: COMPARATOR
Intervention: Fondaparinux s.c.
Number of subjects: 7344
Study 10415058 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticosteroids
Number of subjects: 0
Study 10415058 — intervention group
Group type: COMPARATOR
Intervention: Nasal polyps (control group)
Number of subjects: 0
Study 10415058 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyp tissue fluid
Number of subjects: 0
Study 7480564 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of RS 15385
Number of subjects: 36
Study 7480564 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of RS 15385
Number of subjects: 36
Study 2257249 — intervention group
Group type: COMPARATOR
Intervention: Estrogen treatment for 1 year
Number of subjects: 38
Study 2257249 — intervention group
Group type: COMPARATOR
Intervention: Estro-progestative treatment for 1 year
Number of subjects: 38
Study 2257249 — intervention group
Group type: COMPARATOR
Intervention: Conjugated estrogens treatment for 6 months post-oophorectomy
Number of subjects: 38
Study 7224204 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered anesthesia circuits
Number of subjects: 520
Study 7224204 — intervention group
Group type: COMPARATOR
Intervention: Nonfiltered anesthesia circuits
Number of subjects: 520
Study 30503169 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive measures related to memory and attention
Number of subjects: 312
Study 30503169 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample size calculations for randomized controlled trials
Number of subjects: 312
Study 28279777 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutureless repair
Number of subjects: 39
Study 28279777 — intervention group
Group type: COMPARATOR
Intervention: Sutured repair
Number of subjects: 39
Study 28279777 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 39
Study 26027613 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted multifaceted quality improvement intervention
Number of subjects: 4800
Study 26027613 — intervention group
Group type: COMPARATOR
Intervention: Routine standard of care (control group)
Number of subjects: 4800
Study 24137971 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascoril (combined broncholytic and expectorant drug)
Number of subjects: 60
Study 24137971 — intervention group
Group type: COMPARATOR
Intervention: Ambroxol (mucolytic agent)
Number of subjects: 60
Study 21849822 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiogram interpretation by reader 1 (blinded to troponin)
Number of subjects: 121
Study 21849822 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiogram interpretation by reader 2 (blinded to troponin)
Number of subjects: 121
Study 21849822 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiogram interpretation (reader 1) for specific signs of ischemia
Number of subjects: 121
Study 21849822 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiogram interpretation (reader 2) for specific signs of ischemia
Number of subjects: 121
Study 21849822 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-rater agreement for ischemia (blinded to troponin)
Number of subjects: 121
Study 21849822 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-rater agreement for ischemia (unblinded to troponin)
Number of subjects: 121
Study 20193328 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillation of pirarubicin (THP) at 1 hour before TUR-BT (30 mg/50 ml, 0.5 hours)
Number of subjects: 40
Study 20193328 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillation of pirarubicin (THP) at 24 hours before TUR-BT (30 mg/50 ml, 0.5 hours)
Number of subjects: 40
Study 20193328 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving TUR-BT only
Number of subjects: 40
Study 17426207 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (400 mug/d) for 12 weeks
Number of subjects: 30
Study 17426207 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg) for 12 weeks
Number of subjects: 30
Study 17426207 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 subjects)
Number of subjects: 30
Study 15291681 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 20
Study 12016346 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffuse Muscular Coactivation (DMC) in fibromyalgia sufferers
Number of subjects: 0
Study 12016346 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 12016346 — intervention group
Group type: EXPERIMENTAL
Intervention: Median frequency measurement
Number of subjects: 0
Study 9685826 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-guided fine-needle aspiration (CTNAB)
Number of subjects: 30
Study 9685826 — intervention group
Group type: COMPARATOR
Intervention: Transbronchial fluoroscopy-guided needle aspiration (TBNA)
Number of subjects: 30
Study 9685826 — intervention group
Group type: EXPERIMENTAL
Intervention: CTNAB
Number of subjects: 30
Study 9685826 — intervention group
Group type: COMPARATOR
Intervention: TBNA
Number of subjects: 30
Study 7911736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine 4 mg/m2/day
Number of subjects: 18
Study 7911736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine 6 mg/m2/day
Number of subjects: 18
Study 7911736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine 8 mg/m2/day
Number of subjects: 18
Study 2899509 — intervention group
Group type: EXPERIMENTAL
Intervention: xamoterol 200 mg twice daily
Number of subjects: 14
Study 2899509 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study 31931098 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil therapy
Number of subjects: 212
Study 31931098 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower eGFR
Number of subjects: 212
Study 30695908 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen matrix (CM)
Number of subjects: 19
Study 30695908 — intervention group
Group type: COMPARATOR
Intervention: Free gingival graft (FGG)
Number of subjects: 19
Study 28315160 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (LC) at 2.0 g kg-1 of the diet for 4 weeks prior to MCLR injection
Number of subjects: 5
Study 28315160 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (LC) at 1.0 g kg-1 of the diet for 4 weeks prior to MCLR injection
Number of subjects: 5
Study 28315160 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (LC) at 0.5 g kg-1 of the diet for 4 weeks prior to MCLR injection
Number of subjects: 5